Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease

The Independent UK

PharmaTher Provides Business Highlights And Releases Audited Annual Financials

PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.

Benzinga

The Best Value Stock to Buy for the Long Term

Biopharmaceutical company Bristol-Myers Squibb (BMY) has reported sound financials and possesses a solid upside potential. Given its promising fundamentals, this value stock might be an ideal long-term addition to your portfolio. Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharma manufacturers’ body moves Karnataka HC against treating free samples of medicines given to doctors as ‘freebies’ under Income Tax Act

Ministry of Finance had said that drug manufacturers will have to deduct 10% tax for the value of free samples of medicines

The Hindu

Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29

Reuters

Benzinga

DEA Claims Doctors Requesting Psilocybin For Dying Patients Have Commercial Interests

For the Drug Enforcement Administration (DEA), physicians who seek psilocybin for their dying patients under federal Right to Try (RTT) laws are making a request for a ‘commercial use.’ The DEA is implying that doctors who want to give terminally ill patients psilocybin have a financial interest, making them ineligible for a f

Benzinga

DGCI allows Serum Institute to export malaria vaccine to U.K.

The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine

The Hindu

Read news from The Economist, FT, and more,
with one subscription

2 Earnings Winners to Scoop Up During the Bear Market

The bear market has been brutal. Given the trend in inflation and weakening economy, it's unlikely to end soon. For investors, the best strategy is to use the adverse market conditions to scoop up stocks that have a long-term history of compounding earnings. Therefore, investors should consider buying Builders FirstSource…

StockNews.com

Pfizer COVID vaccine approved for all children aged over six months old

The Therapeutic Goods Administration approves Pfizer's paediatric dose of its COVID vaccine for children aged between six months and five years old.

ABC News

Interim tick for Pfizer infant booster

The Therapeutic Goods Administration has given provisional approval for Pfizer's COVID-19 booster to be used in children aged six months to five years.

AAP

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

Benzinga

Lab Monkeys Are the Latest Covid Shortage

Beijing’s ban on macaque exports—needed to test vaccines and other lifesaving drugs—could give its pharma industry an edge.

Businessweek

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Lawmakers eye lame duck for unfinished business on insulin

WASHINGTON — A bipartisan Senate duo is still working to pass a bill to overhaul insulin prices, but the outlook is complicated by the messy drug pricing system, politics and a busy congressional calendar.

Reuters

Opioid crisis cost U.S. nearly $1.5 trillion in 2020 -congressional report

Fueled by the COVID-19 pandemic, the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow, a congressional report seen by Reuters shows.

Birmingham Post

Pharmaceuticals firm Vectura gets green light for £58m Bristol facility

The Wiltshire-based business specialises in respiratory medicines and inhaler devices

The Guardian - AU

Medicinal cannabis companies fined almost $1m by TGA over false treatment claims

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

DEA: Fake pills containing fentanyl helping drive OD deaths

Federal officials say an increasing number of fake prescription pills containing potentially deadly fentanyl are helping drive overdose death rates to record levels in the U.S. And officials warn that some of the pills are being manufactured in rainbow colors designed to look like candy

ABC News

Pfizer pays $179m for Brisbane company behind smartphone app that claims to diagnose COVID

Recent studies had shown the app had a 92 per cent success rate in diagnosing the virus among symptomatic patients, but more clinical trials were needed for it to gain regulatory approval.

The Independent UK

Millions of Americans will save on Medicare fees next year

For the first time in a decade, Americans will pay less next year on monthly premiums for Medicare’s Part B plan, which covers routine doctors’ visits and other outpatient care

Benzinga

Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family

Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.

Benzinga

Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01

Benzinga

Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session

Gainers

Chronicle Live

Autumn Covid-19 vaccine roll-out to 'double your defences' ahead of uncertain winter

Vulnerable groups may have already been called to have their fourth Covid-19 jab

1 … 124 125 126 127

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.